Erratum
Year: 2022
Type: erratum
Abstract: In the paper by Yu et al. (“Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials.” Alzheimer's Dement. 2022; 8:e12280. https://doi.org/10.1002/trc2.12280), errors occurred in the preparation of the paper for publication, requiring the following corrections. In Table A3B, “Spline P” should have been “Spline P-value.” In Tables 2 and A4, “FDA registered trial” was incorrectly indented in the “Independent variables” column so that it was grouped as one of the “AD stage” variables. It should have been fully left-justified, and the row should have been shaded pink to identify it as a separate independent variable. The corrected tables appear below. We regret the errors.
DOI: 10.1002/trc2.12311
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,200
OpenAlex ID: W4285203087